Efficacy and Safety Evaluation of Sintilimab in Combination With IBI310 as Treatment in Patients With EBV-Positive Gastric Cancer

NCT04202601 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Interventions

DRUG: Sintilimab
DRUG: IBI310

Sponsor

Peking University

Collaborators

[object Object]